RxDoctor Payments Data

Hal Dickson, MD

Neurology · Muncie, INNPI 1992780894

Payments from drug & device makers

$3,525in general payments, 2019–2025

Across 224 payments — averaging $15.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$423
  • Biohaven Pharmaceuticals, Inc.$276
  • Novartis$234
  • Eisai Inc.$221
  • UCB, Inc.$190
  • Lilly USA, LLC$143
  • plus $2K from 41 others

What the payments were for

  • Speaking & faculty fees$191%
  • Food & beverage$3,50799%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,525 in reported general payments places this provider in the 50th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$25,663
Medicare patients
232
Services billed
364

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate12$60,084
XcopriCenobamate18$20,326
Lacosamide22$19,570
Aimovig AutoinjectorErenumab-Aooe14$14,585
Emgality PenGalcanezumab-Gnlm16$11,716
Diazepam12$8,471
Carbidopa-Levodopa ErCarbidopa/Levodopa75$7,835
Levetiracetam114$6,711
Oxcarbazepine67$6,103
DilantinPhenytoin Sodium Extended19$4,083
Tegretol XrCarbamazepine11$3,111
Gabapentin91$2,630
Entacapone17$2,160
Carbidopa-LevodopaCarbidopa/Levodopa47$1,318
Ropinirole Hcl34$1,057

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$83$60,08412 claims
SK Life Science, Inc.Xcopri$56$20,32618 claims
PfizerDilantin$50$4,08319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 308 neurology providers in Indiana.

Other neurology in Muncie

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →